Tuesday September 25, 2018 12:24

Heathcare Press Release : 27 Aug 2018

Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Heathcare—27 Aug 18

Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with